Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Clostridioides difficile Activates Human Mucosal-Associated Invariant T Cells.

Bernal I, Hofmann JD, Bulitta B, Klawonn F, Michel AM, Jahn D, Neumann-Schaal M, Bruder D, Jänsch L.

Front Microbiol. 2018 Oct 25;9:2532. doi: 10.3389/fmicb.2018.02532. eCollection 2018.

2.

Proteomic definition of human mucosal-associated invariant T cells determines their unique molecular effector phenotype.

Bulitta B, Zuschratter W, Bernal I, Bruder D, Klawonn F, von Bergen M, Garritsen HSP, Jänsch L.

Eur J Immunol. 2018 Aug;48(8):1336-1349. doi: 10.1002/eji.201747398. Epub 2018 May 30.

3.

Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study.

Zabana Y, Mañosa M, Cabré E, Bernal I, Marín L, Lorenzo-Zúñiga V, Moreno V, Boix J, Domènech E.

J Gastroenterol Hepatol. 2014;29(7):1413-7. doi: 10.1111/jgh.12579.

PMID:
24627958
4.

[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU].

Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU).

Gastroenterol Hepatol. 2013 Oct;36(8):e1-47. Spanish. No abstract available.

PMID:
24215088
5.

Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Mañosa M, Cabré E, Bernal I, Esteve M, Garcia-Planella E, Ricart E, Peñalva M, Cortes X, Boix J, Piñol M, Gassull MA, Domènech E.

Inflamm Bowel Dis. 2013 Aug;19(9):1889-95. doi: 10.1097/MIB.0b013e31828ef13f.

PMID:
23689809
6.

Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids.

Mañosa M, Cabré E, Garcia-Planella E, Bernal I, Gordillo J, Esteve M, Zabana Y, Gassull MA, Domènech E.

Inflamm Bowel Dis. 2011 Dec;17(12):2497-502. doi: 10.1002/ibd.21634. Epub 2011 Apr 6.

PMID:
21472824
7.

Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients.

Navarro-Llavat M, Domènech E, Bernal I, Sánchez-Delgado J, Manterola JM, Garcia-Planella E, Mañosa M, Cabré E, Gassull MA.

Digestion. 2009;80(1):25-9. doi: 10.1159/000212076. Epub 2009 May 14.

PMID:
19439968
8.

Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.

Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC; Biobadaser group.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):854-9.

PMID:
19032819
9.

Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy.

Domènech E, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA.

Inflamm Bowel Dis. 2008 Oct;14(10):1373-9. doi: 10.1002/ibd.20498.

PMID:
18452205
10.

Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study.

Domènech E, Mañosa M, Bernal I, Garcia-Planella E, Cabré E, Piñol M, Lorenzo-Zúñiga V, Boix J, Gassull MA.

Inflamm Bowel Dis. 2008 Apr;14(4):508-13. doi: 10.1002/ibd.20359. Erratum in: Inflamm Bowel Dis. 2008 Dec;14(12):1761.

PMID:
18183602
11.

[Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease].

García-Planella E, Marín L, Domènech E, Bernal I, Mañosa M, Zabana Y, Gassull MA.

Med Clin (Barc). 2007 Jan 20;128(2):45-8. Spanish.

PMID:
17266900
12.

Medication-taking behavior in a cohort of patients with inflammatory bowel disease.

Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, Cabré E, Gassull MA.

Dig Dis Sci. 2006 Dec;51(12):2165-9. Epub 2006 Nov 4.

PMID:
17086434
13.

Predictors of clinical response to systemic steroids in active ulcerative colitis.

Bernal I, Mañosa M, Domènech E, Garcia-Planella E, Navarro M, Lorenzo-Zúñiga V, Cabré E, Gassull MA.

Dig Dis Sci. 2006 Aug;51(8):1434-8. Epub 2006 Jul 26.

PMID:
16868820
14.

Abdominal aortitis associated with Crohn's disease.

Domènech E, Garcia-Planella E, Olazábal A, Sánchez-Delgado J, Zabana Y, Bernal I, Mañosa M, Olivé A, Gassull MA.

Dig Dis Sci. 2005 Jun;50(6):1122-3. No abstract available.

PMID:
15986866
15.

Infliximab for the treatment of chronic anemia in Crohn's disease.

Domènech E, Mañosa M, Masnou H, Navarro M, Garcia-Planella E, Bernal I, Gassull MA.

Am J Gastroenterol. 2005 Feb;100(2):496. No abstract available.

PMID:
15667513
16.

Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).

Garcia-Planella E, Domènech E, Esteve-Comas M, Bernal I, Cabré E, Boix J, Gassull MA.

Eur J Gastroenterol Hepatol. 2003 Apr;15(4):351-4.

PMID:
12655253
17.

[Intravenous cyclosporine A in the treatment of refractory Crohn's disease].

García-Planella E, Domènech E, Cabré E, Bernal MI, Gassull MA.

Med Clin (Barc). 2002 Nov 9;119(16):610-2. Spanish.

PMID:
12433336

Supplemental Content

Loading ...
Support Center